Background: Hemoglobinopathies are priority genetic diseases for prevention programs. Beta thalassaemia major is one of the
Introduction
Thalassaemia and haemoglobinopathies, a group of autosomal-recessive inherited human disorders, are prevalent in many parts of the world. Heterozygote screening and genetic counseling are essential for the prevention and control of severe thalassaemia diseases. (1) At molecular level, β-thalassaemia represents a great heterogeneity as more than 380 mutations have been identified for the β -globin gene responsible for this disease (OMIM, 2005) . (2) Despite this heterogeneity, each at-risk population has its own spectrum of common mutations, usually from 5 to 10, a finding that simplifies mutation analysis. (3) As the ethnic composition of the Indian population is varied and complex (4) , each region of the country has its own distinct set of mutations (5) .
Homozygosity for β-thalassaemias usually results in transfusion-dependent thalassaemia major and, rarely, in mild non-transfusion-dependent conditions. 
Subjects and Methods
The parents were confirmed β-thalassaemia carriers as they had an affected child with transfusiondependent β-thalassaemia. 50 samples from parents including 29 paternal and 21 maternal samples were taken for screening of five common Indian β-thalassaemia mutations from 30 families. Thirty three samples including 22 males and 11 females were also collected from their second or third child i.e. total 83 samples were collected including father, mother and siblings of thirty thalassaemia major's families.
DNA Isolation
DNA isolation from the buffy coat cells of EDTAanticoagulated blood samples was done as described (14) . The genomic DNA was extracted from peripheral blood samples by standard proteinase K/ sodium dodecyl-sulphate (SDS) digestion followed by phenol-chloroform extraction (15) or salt precipitation method. (16) 
Detection of Mutations
The mutations were characterized by the PCR method employing allele specific priming technique (AMRS) described by Newton et al (14) which has been adopted to study the thalassaemia mutations (13, 14, 17) . Five mutations, namely IVS-I-5 (G→C), IVS-I-1(G→T), CD 41/42 (-TCTT), CD 8/9(+G) and ∆ 619 bp deletion from the 3' end of the ß-globin gene were screened. All the primers used were procured from HiMedia. A total of 7 different primers were used. In this technique presence of amplification product indicates mutation.
Validation of ARMS PCR
The ARMS PCR was validated by using negative and positive control samples. Fragments were separated in ethidium bromide stained agarose gels and results were documented in a Gel Documentation system (Perkin Elmer). PCR assays were reproduced at least twice for confirmation.
Data analysis
Presence of bands in both wild-type and mutant PCR assay was inferred as a heterozygous mutant for the particular mutation concerned. Frequency distribution was calculated and comparisons were made in Excel spreadsheets (Microsoft).
Results
In this study, molecular characterization of all samples collected from parents and siblings of thalassaemia major index cases was done to identify the proportion of thalassaemia carriers as well as the (+G)with 4.8%. 5% mutations were still remains uncharacterized in the study.
Discussion
Preventive screening programmes to identify carriers are being used by many countries where thalassaemia is a common disease. The incidence of β-thalassaemia has decreased significantly after the introduction of screening programmes. 
Conclusion
This study concludes that screening of immediate family members of thalassaemia patients is more 
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